RTP Mobile Logo
National NHL Tumor Board: Clinical Investigators Provide Their Perspectives on Current Cases of Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Released May 2011

Proceedings from a live event featuring didactic faculty presentations and panel discussions of individual patient cases focusing on all factors that influence multidisciplinary treatment decision-making for the management of follicular lymphoma, diffuse large B-cell lymphoma, chronic lymphocytic leukemia and mantle-cell lymphoma.

CE Disclosures and Faculty Information

  • TARGET AUDIENCE

    This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL) and mantle-cell lymphoma (MCL).

    LEARNING OBJECTIVES

    • Appraise recent data on therapeutic advances and changing practice standards in non-Hodgkin lymphoma (NHL), including CLL, and integrate this information into current clinical care when appropriate.
    • Apply the results of emerging clinical research to the selection of optimal systemic therapy for patients with newly diagnosed and relapsed or refractory CLL.
    • Develop an algorithm for the risk-stratified induction treatment of DLBCL and MCL, and offer evidence-based systemic alternatives at the time of disease relapse.
    • Identify patients with NHL who may experience quantitative and qualitative benefit from stem cell transplantation.
    • Use prognostic and predictive clinical and molecular markers to aid in treatment decision-making for NHL.
    • Employ case-based learning to individualize the use of maintenance and/or consolidation therapy in the management of newly diagnosed and relapsed FL.
    • Recall the emerging data for novel agents and combinations in the treatment of NHL.
    • Delineate areas of heterogeneity in the current management of NHL, and recognize the clinical evidence to support multiple acceptable treatment strategies.
    • Counsel appropriately selected patients about participation in ongoing clinical research studies.

    ACCREDITATION STATEMENT

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY

    CME credit is no longer available for this issue

    This CME activity consists of a video component. The participant should watch the video content.

    CONTENT VALIDATION AND DISCLOSURES

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

    M Ali Ansari-Lari, MD, PhD
    Director of Hematopathology
    Pathology Consultants of South Broward
    Memorial Healthcare System
    Hollywood, Florida

    No real or apparent conflicts of interests to disclose.

    Myron S Czuczman, MD
    Head, Lymphoma/Myeloma Service
    Head, Lymphoma Translational Research Laboratory
    Roswell Park Cancer Institute
    Professor of Medicine
    School of Medicine and Biomedical Sciences
    State University of New York at Buffalo
    Buffalo, New York

    Advisory Committee: Amgen Inc, Biogen Idec, Celgene Corporation, Cephalon Inc, Genentech BioOncology, GlaxoSmithKline, Lilly USA LLC, Millennium — The Takeda Oncology Company, Novartis Pharmaceuticals Corporation; Lectures: Biogen Idec, Genentech BioOncology.

    Jonathan W Friedberg, MD, MMSc
    Associate Professor of Medicine and Hematology
    Chief, Hematology/Oncology Division
    James P Wilmot Cancer Center
    University of Rochester
    Rochester, New York

    Advisory Committee: Genentech BioOncology; Consulting Agreements: Allos Therapeutics, Astellas Pharma US Inc, Calistoga Pharmaceuticals Inc, EMD Serono Inc, Seattle Genetics; Data Safety Monitoring Board: Lilly USA LLC; Research Support: Cephalon Inc, Millennium — The Takeda Oncology Company; Stock Ownership: Bristol-Myers Squibb Company.

    Stephanie A Gregory, MD
    The Elodia Kehm Chair of Hematology
    Professor of Medicine
    Director, Section of Hematology
    Rush University Medical Center/Rush University
    Chicago, Illinois

    Advisory Committee: Cephalon Inc; Consulting Agreements: Amgen Inc, Genentech BioOncology, Novartis Pharmaceuticals Corporation, Spectrum Pharmaceuticals Inc; Speakers Bureau: Cephalon Inc, Genentech BioOncology.

    Lowell L Hart, MD
    Medical Oncologist
    Research Director
    Florida Cancer Specialists
    Fort Myers, Florida

    Speakers Bureau: AstraZeneca Pharmaceuticals LP, Eisai Inc, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Sanofi-Aventis.

    Neil B Horner, MD
    Chief of Neuroradiology
    Atlantic Neuroscience Institute
    Overlook Hospital
    Summit, New Jersey

    No real or apparent conflicts of interest to disclose.

    Atif M Hussein, MD
    Hematologist; Medical Director
    Memorial Cancer Institute
    Hollywood, Florida

    No real or apparent conflicts of interest to disclose. 

    George Labban, MD
    Medical Oncologist
    Memorial Healthcare System
    Hollywood, Florida

    No real or apparent conflicts of interest to disclose.

    Miles B Levin, MD
    Pathologist
    Assistant Attending
    Diplomat of the American Board of Pathology, Anatomic and Clinical Pathology
    Diplomat of the American Board of Pathology, Hematopathology
    Atlantic Health at Overlook Hospital
    Summit, New Jersey

    No real or apparent conflicts of interest to disclose.

    Steven E Levine, MD, FACP

    Pathologist
    Lee Memorial Hospital System
    Fort Myers, Florida

    No real or apparent conflicts of interest to disclose.

    David G Maloney, MD, PhD
    Member, Clinical Research Division
    Fred Hutchinson Cancer Research Center
    Professor of Medicine, Division of Oncology
    University of Washington
    Seattle, Washington

    Advisory Committee: Genentech BioOncology, GlaxoSmithKline, Roche Laboratories Inc, Spectrum Pharmaceuticals Inc.

    Neil Morganstein, MD
    Medical Oncologist
    Medical Diagnostic Associates
    Summit, New Jersey

    No real or apparent conflicts of interest to disclose.

    Sophie D Morse, MD, MSc
    Medical Oncologist
    Medical Diagnostic Associates
    Summit, New Jersey

    No real or apparent conflicts of interest to disclose.

    Neil Nagovski, MD
    Hematologist-Oncologist
    Memorial Cancer Institute
    Pembroke Pines, Florida

    No real or apparent conflicts of interest to disclose. 

    Thomas G Presbrey, MD
    Diagnostic Radiologist
    Florida Radiology Consultants
    Lee Memorial Health System
    Fort Myers, Florida

    No real or apparent conflicts of interest to disclose.

    Mathias J Rummel, MD, PhD
    Head, Department for Hematology
    Hospital of the Justus-Liebig University
    Gießen, Germany

    Advisory Committee: Amgen Inc, Cephalon Inc, GlaxoSmithKline.

    Efrosyni Sfakianaki, MD
    Radiologist
    Diplomat ABR, ABNM, ABIM
    Assistant Professor of Radiology
    Division of Nuclear Medicine
    University of Miami Miller School of Medicine
    Miami, Florida
    Radiologist, PET Imaging Institute of South Florida
    Radiology Associates of Hollywood
    Memorial Healthcare System
    Hollywood, Florida

    No real or apparent conflicts of interest to disclose.

    Mitchell R Smith, MD, PhD
    Director, Lymphoma Service
    Fox Chase Cancer Center
    Philadelphia, Pennsylvania

    Advisory Committee: Cephalon Inc, Wyeth; Speakers Bureau: Allos Therapeutics, Celgene Corporation, Cephalon Inc, Genentech BioOncology, Millennium — The Takeda Oncology Company, Spectrum Pharmaceuticals Inc.

    MODERATOR Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abraxis BioScience Inc, a wholly owned subsidiary of Celgene Corporation, Allos Therapeutics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, Lilly USA LLC, Millennium — The Takeda Oncology Company, Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi-Aventis and Seattle Genetics.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This program is supported by educational grants from Cephalon Inc, Genentech BioOncology/Biogen Idec and Millennium — The Takeda Oncology Company.

    Hardware/Software Requirements:
    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: May 2011
    Expiration date: May 2012

    This presentation was selected by the American Society of Hematology® as an independent educational activity held adjunct to the ASH Annual Meeting. This presentation is not sponsored or endorsed by ASH.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):